VLGC Virologic (MM)

ViroLogic Added to the NASDAQ Biotechnology Index SOUTH SAN FRANCISCO, Calif., May 20 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced today that it will be added to the NASDAQ Biotechnology Index(R) (NASDAQ:NBI) effective with the market open on May 23, 2005. All securities are classified according to the FTSE Global Classification System(TM) as biotechnology or pharmaceutical. Index eligibility criteria include listing on the NASDAQ National Market(R) and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com/ . About ViroLogic ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biotechnology and pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.virologic.com/. FORWARD LOOKING STATEMENTS Certain statements in this press release are forward-looking, including statements regarding the addition of ViroLogic to the NASDAQ Biotechnology Index. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the development of future products; the performance of our products; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; whether larger studies involving tumor samples will yield favorable results regarding the predictive capability of eTag assays for responsiveness to cancer drugs; our ability to establish reliable, high-volume operations at commercially reasonable costs; our ability to introduce a product commercially in 2006; our ability to successfully integrate the operations of ACLARA into our operations; competition from larger more established diagnostic providers; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the level of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for our products; whether the FDA or any other agency will seek to regulate ViroLogic's in house clinical laboratory testing; our ability to comply with FDA regulations in order to establish and maintain diagnostic kit manufacturing operations; whether we will encounter problems or delays in establishing and validating eTag assays within our clinical laboratory; whether we will encounter problems or delays in automating our processes or expanding our capacity; whether the intellectual property underlying the Company's technology is adequate; whether we may be deemed to infringe on the intellectual property of others and whether licenses to third party technology will be available; whether ViroLogic is able to build brand loyalty and expand revenues; the potential impact of any payments under the CVRs on our common stock and capital resources; and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. DATASOURCE: ViroLogic, Inc. CONTACT: Alfred Merriweather, Vice President and CFO of ViroLogic, Inc., +1-650-635-1100; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065, or , for ViroLogic, Inc. Web site: http://www.virologic.com/

Copyright